Danvatirsen
AML/MDS
Montefiore Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the AML/MDS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Midostaurin Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 | CCC |
Decitabine Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 | CCC |
Azacitidine Newave Pharmaceutical Inc | Phase 1 | CC |
lp-108 Newave Pharmaceutical Inc | Phase 1 | CC |
Mana 312 Mana Therapeutics | Phase 1 | CC |
View all 13 →
Same molecule, other indications
Danvatirsen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →